Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) will announce its earnings results before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the firm earned ($0.26) EPS. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Acurx Pharmaceuticals Price Performance
NASDAQ ACXP opened at $3.85 on Friday. The firm has a market cap of $50.09 million, a PE ratio of -3.41 and a beta of -1.62. Acurx Pharmaceuticals has a one year low of $1.17 and a one year high of $8.82. The stock’s 50 day simple moving average is $3.00 and its 200 day simple moving average is $2.66.
Analyst Upgrades and Downgrades
Institutional Trading of Acurx Pharmaceuticals
An institutional investor recently raised its position in Acurx Pharmaceuticals stock. BlackRock Inc. grew its holdings in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) by 149.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,699 shares of the company’s stock after purchasing an additional 10,014 shares during the quarter. BlackRock Inc. owned approximately 0.16% of Acurx Pharmaceuticals worth $55,000 at the end of the most recent reporting period. Institutional investors own 11.28% of the company’s stock.
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
- Five stocks we like better than Acurx Pharmaceuticals
- How to Invest in Cybersecurity
- MarketBeat Week in Review – 11/6 – 11/10
- How to Invest in Esports
- Data giants MongoDB and Snowflake just got upgraded
- Pros And Cons Of Monthly Dividend Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.